CD8A and neoplasm: Furthermore, monoclonal antibody (mAb) therapy against CCR8 significantly reduced de novo induction and suppressive function of Tregs without affecting CD8+ T cells, delayed tumor growth, and improved long-term survival in CRC mouse models [60].